Profil bibliographique

Yong Zhang

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

7Publications signalées
29Citations signalées
0Affiliations récentes

Les domaines associés

Peptidase Inhibition and AnalysisSarcoma Diagnosis and TreatmentLung Cancer Research StudiesSurgical site infection preventionCancer Research and Treatments

Les publications récentes

Accès ouvert 2023 article OpenAlex

Insight of a lipid metabolism prognostic model to identify immune landscape and potential target for retroperitoneal liposarcoma

Zhenyu Wang, Ping Tao, Peidang Fan, Jiongyuan Wang et autres

Introduction: The exploration of lipid metabolism dysregulation may provide novel perspectives for retroperitoneal liposarcoma (RPLS). In our study, we aimed to investigate potential targets and facilitate further understanding of immune landscape in RPLS, through lipid metabolism-associated genes (LMAGs) based prognostic model. Methods: …

cn (code pays fourni par la source)

8 citations Frontiers in Immunology
Accès ouvert 2023 other OpenAlex

Data from Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial

Zhi-ming Wang, Rongyuan Zhuang, Xi Guo, Chen-lu Zhang et autres

AbstractPurpose: The treatment outcome for locally advanced or metastatic soft-tissue sarcoma (STS) remains unsatisfactory. Anlotinib had demonstrated impressive activity in the subsequent-line treatment of STS. This study investigated the combination of anlotinib and epirubicin followed by anlotinib maintenance as first-line treatment for …

cn (code pays fourni par la source)

0 citations
Accès ouvert 2023 other OpenAlex

Data from Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial

Zhi-ming Wang, Rongyuan Zhuang, Xi Guo, Chen-lu Zhang et autres

AbstractPurpose: The treatment outcome for locally advanced or metastatic soft-tissue sarcoma (STS) remains unsatisfactory. Anlotinib had demonstrated impressive activity in the subsequent-line treatment of STS. This study investigated the combination of anlotinib and epirubicin followed by anlotinib maintenance as first-line treatment for …

0 citations
Accès ouvert 2022 article OpenAlex

Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial

Zhi-ming Wang, Rongyuan Zhuang, Xi Guo, Chen-lu Zhang et autres

PURPOSE: The treatment outcome for locally advanced or metastatic soft-tissue sarcoma (STS) remains unsatisfactory. Anlotinib had demonstrated impressive activity in the subsequent-line treatment of STS. This study investigated the combination of anlotinib and epirubicin followed by anlotinib maintenance as first-line treatment for …

cn (code pays fourni par la source)

21 citations Clinical Cancer Research
Profil ORCIDNotice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.